

medicines  
patent  
pool

# **The mRNA Technology Transfer Programme: towards a better prepared global South**

*António Lima Grilo, Ph.D.*

*Washington D.C., 30 January 2025*

MEDICINESPATENTPOOL.ORG

# About the Medicines Patent Pool (MPP)

*Founded in 2010, MPP is a **United Nations-backed** public health organisation working to **increase access to and to facilitate the development of life-saving medicines** for low- and middle-income countries (LMICs) through voluntary licensing and technology transfer.*

## Vision



A **world** in which **people** in need in **LMICs** have **rapid access to effective and affordable medical treatments** and health technologies.

## Mission



Our mission is to **increase equitable access to innovative medicines** and other health technologies **through public health-oriented voluntary licensing and technology transfer.**

## Mandate



MPP's mandate covers **patented medicines for both infectious diseases and non-communicable diseases** including treatments and technologies.





# The footprint and the success of MPP public-health driven licenses

**22**  
patent  
holders

signed agreements  
with MPP  
(2010 - 2023)



Janssen

Pfizer

abbvie

SHIONOGI

MSD

NOVARTIS

Boehringer  
Ingelheim

GILEAD

Bristol-Myers Squibb

Roche

ViiV  
Healthcare

*Not exhaustive*

**43 billion**  
treatment doses  
supplied




in the 2012 -  
2023 period

**1.9 billion \$**  
dollars saved



through  
MPP's licences  
(2012 - 2023)

**72**  
manufacturers  
and product  
developers  
have sublicences  
from MPP



**148**  
countries



have benefited  
from access to  
MPP's products

**170,000**  
deaths averted



projected  
by 2030

# 5 years ago: a Pandemic



**In LMICs, the impact was disproportionately greater:**

- Scarce access to raw materials amplified by protectionist policies
- Limited end-to-end vaccine manufacturing capacity (mostly DP)
- Lack of a trained workforce
- Underdeveloped supply chains


**“**  
*What we have before a Pandemic is what we have during the Pandemic.*

# Our Model

## Multilateral Technology Transfer

to public and private  
organisations.

Faster, broader access and  
resource-efficient  
approach.



- 1 Afrigen
- 2 Biovac
- 3 Biovax
- 4 Bio-Manguinhos
- 5 Biofarma
- 6 BiologicalE
- 7 BioGeneric Pharma
- 8 Biovaccines Nigeria
- 9 Darnitsa
- 10 Incepta Vaccine
- 11 Institute Pasteur de Dakar
- 12 Institute Pasteur de Tunis
- 13 Institute Torlak
- 14 National Institute of Health
- 15 Polyvac
- 16 Sinergium Biotech

 CMOs

# mRNA Programme Core Objectives

## FUTURE PANDEMIC PREPAREDNESS

**mRNA TECHNOLOGY  
PLATFORM  
DEVELOPMENT and  
INDUSTRIALISATION**

**TECHNOLOGY  
TRANSFER to  
PROGRAMME  
PARTNERS**

**Strengthening  
LOCAL PRODUCTION**

## INTER-PANDEMIC SUSTAINABILITY

- ❖ Disease targets relevant for LMICs
- ❖ Next generation technologies
- ❖ Knowledge sharing
- ❖ Collaborative development

# Work on the ground



**Local Capacity Building** in 15 countries: 2 in LATAM, 6 in Africa, 5 in SE Asia and 2 in Eastern Europe partly funded by the programme will benefit from the mRNA platform developed in SA.

**Time and Expertise** of MPP and WHO staff and consultants working on-the-ground with all partners.



**Knowledge Spillover** to local Universities and start up companies working on **new disease targets, next generation lipids, local raw material manufacturing.**

**Interpandemic sustainability** of new facilities through the creation of region-specific R&D consortia (LATAM, SE Asia, EMRO...)



**Work with key suppliers** to negotiate **preferential pricing** and understand how **new supply chain routes** can support mRNA Programme manufacturing partners.

**Capacitation of local NRAs** with WHO's support so that they can be autonomous for the evaluations of dossiers and licensing of sites.





# Future

Licensing opportunities & sustainability.

- Process technology
- Lipids
- mRNA Therapeutics





# What have we done ?

14

New mRNA development and/or manufacturing sites by 2026

10

GMP-approved mRNA vaccine manufacturing sites by 2030

>150

Hands-on trained staff + knowledge spillover by 2026

>10

R&D consortia working on new disease targets and technology innovations

> 5

Key global suppliers established new supply chains and provided preferential pricing

>10

External R&D partners enrolled in sustainability efforts




KINGDOM OF BELGIUM  
[www.diplomatie.belgium.be](http://www.diplomatie.belgium.be)



TORLAK Institut za virusologiju, vakcine i serume





medicines  
patent  
pool

# Thank you very much.



Schweizerische Eidgenossenschaft  
Confédération suisse  
Confederazione Svizzera  
Confederaziun svizra

Swiss Agency for Development  
and Cooperation SDC



MINISTÈRE  
DE L'EUROPE  
ET DES AFFAIRES  
ÉTRANGÈRES  
*Liberté  
Égalité  
Fraternité*



MOFA  
Japan



german  
cooperation  
DEUTSCHE ZUSAMMENARBEIT

[MEDICINESPATENTPOOL.ORG](https://www.medicinespatentpool.org)



[YOUTUBE.COM/USER/MEDICINESPATENTPOOL](https://www.youtube.com/user/MedicinesPatentPool)



[WWW.LINKEDIN.COM/COMPANY/MEDICINES-PATENT-POOL/](https://www.linkedin.com/company/medicines-patent-pool/)



[YOUTUBE.COM/USER/MEDICINESPATENTPOOL](https://www.youtube.com/user/MedicinesPatentPool)